Helix

Helix is a leading population genomics company operating at the intersection of clinical care, research, and genomics. Its end-to-end platform empowers health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical practice. The company leverages one of the world's largest CLIA/CAP next-generation sequencing labs and its proprietary Exome+ assay to support comprehensive population genomics initiatives, including patient recruitment, engagement, return of clinically actionable disease screening results, and basic/translational research. Founded in 2015, Helix has established itself as a key player in the genomics sector, aiming to make genomic insights accessible and actionable.

The company's operational capabilities extend to all facets of population genomics. Helix supports recruitment and engagement strategies, provides clinically actionable disease screening, facilitates the return of results, and drives both basic and translational research. Its proprietary Exome+ assay and extensive sequencing lab infrastructure are central to these operations. To understand the human capital driving these advancements, you can Meet Helix's team for insights into their leadership and expertise. Helix operates with an employee range of 500 - 1,000 individuals across its 11 locations, indicating a significant operational footprint and a commitment to scaling its services.

Financially, Helix has secured substantial investment, including a $200 million Series B in 2018 and a $50 million Series C in 2021, underscoring investor confidence in its growth trajectory. The company reported a revenue of $128.9 million. Its competitive landscape includes entities like Fulgent Genetics, Ambry Genetics, and Caris Life Sciences, all operating within theView more...